Courts, regulators and legislatures are redrawing what pharmacies are paid, what they are liable for and which drugs they can dispense. Here are six developments from recent weeks.
- States are policing PBM payments to pharmacies. Oklahoma will distribute more than $2.1 million to more than 900 pharmacies from a CVS Caremark settlement over transaction fees allegedly charged in violation of state law. It is the third settlement with the PBM, bringing the total returned to Oklahoma pharmacies to more than $7 million. Louisiana reached a $45 million settlement with CVS in February, and Florida’s attorney general issued a civil investigative demand over steering and reimbursement disparities.
- CMS wants to define fair Part D pharmacy contracts. CMS is collecting comments through Nov. 23 on what counts as “reasonable and relevant” Part D pharmacy contract terms, including reimbursement, dispensing fees, audits and 340B, ahead of standards that apply starting in 2029. The Consolidated Appropriations Act of 2026’s any-willing-pharmacy requirement also begins that year.
- State payment caps are testing pharmacy margins. Maryland’s drug affordability board approved the first state payment limits on Ozempic and Jardiance for state and local government purchasers, effective Jan. 1, 2027. A community pharmacy group warned the limits could mean government purchasers pay pharmacies less even if pharmacies pay wholesalers the same, and the board said it will evaluate pharmacy friction after implementation.
- Opioid liability is reaching pharmacy practice. A Washington judge ordered Albertsons to pay $900 million after finding its pharmacies failed to resolve red flags of opioid diversion, with the state citing understaffing and discount card use. Albertsons disagrees and is considering an appeal.
- Compounding policy is being contested. HHS said it does not intend to take enforcement action against pharmacies that compound six unapproved peptides under certain conditions, and the American Medical Association adopted a policy urging HHS to rescind directives easing restrictions on unapproved peptides and to push enforcement against compounding pharmacies and telehealth platforms.
- Coverage decisions are changing dispensing volume. Weight loss GLP-1 prescriptions fell about 84% in four states that ended Medicaid coverage, compared with states that kept it. Eligible patients’ options include a Walgreens program that adds insurance navigation, prior authorization support and pharmacist follow-up for patients starting GLP-1s.